| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/02/2010 | EP2191824A1 Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| 06/02/2010 | EP2191823A1 Methods for improving bioavailability of a renin inhibitor |
| 06/02/2010 | EP2191822A1 Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine |
| 06/02/2010 | EP2191821A1 Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation |
| 06/02/2010 | EP2191820A1 Pharmaceutical formulations of meloxicam |
| 06/02/2010 | EP2191733A1 Nutrition containing fat blend |
| 06/02/2010 | EP2191718A1 Compounds and uses for the treatment of airway diseases and for the delivery of airway drugs |
| 06/02/2010 | EP2190994A2 Compositions comprising stat3 sirna and methods of use thereof |
| 06/02/2010 | EP2190993A2 Compositions comprising stat5 sirna and methods of use thereof |
| 06/02/2010 | EP2190991A2 Sdf-1 binding nucleic acids and the use thereof |
| 06/02/2010 | EP2190990A1 Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
| 06/02/2010 | EP2190985A1 Cancer-related genes, cdca5, epha7, stk31 and wdhd1 |
| 06/02/2010 | EP2190884A1 Process for preparing thermosensitive (poly(ethylene oxide) poly(propylene oxide)) derivatives that can be used to functionalize chitosan. |
| 06/02/2010 | EP2190858A2 Urea-containing peptides as inhibitors of viral replication |
| 06/02/2010 | EP2190852A1 Bicyclic sphingosine 1-phosphate analogs |
| 06/02/2010 | EP2190850A1 Small molecule correctors of deltaf508 cftr trafficking |
| 06/02/2010 | EP2190849A2 Compounds useful as protein kinases inhibitors |
| 06/02/2010 | EP2190848A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands |
| 06/02/2010 | EP2190847A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as nicotinic acetylcholine receptor ligands |
| 06/02/2010 | EP2190846A1 1,4-diaza-bicycl0(3.2.2)n0nyl pyrimidinyl derivatives useful as nicotinic acetylcholine- receptor ligands |
| 06/02/2010 | EP2190845A2 Hdac inhibitors |
| 06/02/2010 | EP2190843A1 Benzimidazole nf- kappab inhibitors |
| 06/02/2010 | EP2190842A1 Polymorph forms of (s)-2-((4-benzofuranyl)carbonylaminomethyl)-1-((4-(2-methyl-5-(4-fluorophenyl)thiazolyl)carbonyl)piperidine |
| 06/02/2010 | EP2190841A1 Substituted oxazolidinone derivatives |
| 06/02/2010 | EP2190840A2 Chemical compounds 979 |
| 06/02/2010 | EP2190837A1 4-pyrimidinesulfamide derivative |
| 06/02/2010 | EP2190836A1 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors |
| 06/02/2010 | EP2190835A1 Adrenergic compounds |
| 06/02/2010 | EP2190834A1 Pyridoneamide derivatives as focal adhesion kinase (fak) inhibitors and their use for the treatment of cancer |
| 06/02/2010 | EP2190833A1 Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors |
| 06/02/2010 | EP2190831A2 Method for the production of 1,3-dioxolane-2-ones and carboxylic acid esters by means of transacylation in basic reaction conditions |
| 06/02/2010 | EP2190827A1 N-benzyl, n' -arylcarbonylpiperazine derivatives as lxr modulators |
| 06/02/2010 | EP2190826A2 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors |
| 06/02/2010 | EP2190825A1 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors |
| 06/02/2010 | EP2190824A1 Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| 06/02/2010 | EP2190822A2 5-membered heterocyclic compounds as proton pump inhibitors |
| 06/02/2010 | EP2190820A2 Substituted azepine- and diazepine-sulfonamides useful to inhibit 11beta-hydroxysteroid dehydrogenase type-1 |
| 06/02/2010 | EP2190819A1 Quaternary opioid carboxamides |
| 06/02/2010 | EP2190817A1 3-azabicyclo (4.1.0) heptane derivatives useful as norepinephrine, serotonin or dopamine reuptake inhibitors |
| 06/02/2010 | EP2190816A1 Non-peptidic promoters of apoptosis |
| 06/02/2010 | EP2190815A1 Pyrrolidine aryl-ether as nk3 receptor antagonists |
| 06/02/2010 | EP2190814A1 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| 06/02/2010 | EP2190813A1 Carbamate stereoisomer |
| 06/02/2010 | EP2190811A1 Renin inhibitors |
| 06/02/2010 | EP2190810A1 Compounds isolated from antrodia cinnamomea and use thereof |
| 06/02/2010 | EP2190534A1 Derivatives of 5-amino-4, 6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
| 06/02/2010 | EP2190483A1 Method of reducing the effects of cytostatic drugs on bone marrow derived cells, and methods of screening |
| 06/02/2010 | EP2190481A2 Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
| 06/02/2010 | EP2190475A1 Methods of enhancing adjuvanticity of vaccine compositions |
| 06/02/2010 | EP2190441A1 Polymers with bio-functional self assembling monolayer endgroups for therapeutic applications and blood filtration |
| 06/02/2010 | EP2190440A1 Combination motif immune stimulatory oligonucleotides with improved activity |
| 06/02/2010 | EP2190439A2 Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity |
| 06/02/2010 | EP2190438A2 Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
| 06/02/2010 | EP2190437A2 Use of vitamin b12 for treatment of mucosal lesions |
| 06/02/2010 | EP2190436A2 Sulfasalazine formulations in a biodegradable polymer carrier |
| 06/02/2010 | EP2190435A2 Treatment of sleep disorders |
| 06/02/2010 | EP2190434A2 Purin derivatives for use in the treatment of fab-related diseases |
| 06/02/2010 | EP2190433A2 Therapy for complications of diabetes |
| 06/02/2010 | EP2190432A2 Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors |
| 06/02/2010 | EP2190430A1 Use of compounds derived from cycloheximide for the treatment or prevention of, in particular, ischaemias and cardiopathies |
| 06/02/2010 | EP2190429A1 A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| 06/02/2010 | EP2190427A1 Use of tocopherol derivatives as inhibitors of the notch signalling pathway |
| 06/02/2010 | EP2190426A1 Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering |
| 06/02/2010 | EP2190425A2 Topically applicable fungicide agents for treating nails |
| 06/02/2010 | EP2190424A2 Use of a monoterpene to increase tissue repair |
| 06/02/2010 | EP2190423A2 Arabinoxylo-oligosaccharides useful against gastrointestinal infections |
| 06/02/2010 | EP2190421A2 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases |
| 06/02/2010 | EP2190419A1 Multi particulate matrix system containing galantamine |
| 06/02/2010 | EP2190418A1 Immediate release and sustained release ibuprofen dosing regiment |
| 06/02/2010 | EP2190416A1 Method and composition for making an orally disintegrating dosage form |
| 06/02/2010 | EP2190412A2 Liposome formulations of boronic acid compounds |
| 06/02/2010 | EP2190411A2 Liposome compositions for in vivo administration of boronic acid compounds |
| 06/02/2010 | EP2190410A2 Use of carbon nanotube for drug delivery |
| 06/02/2010 | EP2190409A1 Delivery of drug combinations |
| 06/02/2010 | EP2190408A2 Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation |
| 06/02/2010 | EP2190289A2 Isoxazoline compositions and their use as antiparasitics |
| 06/02/2010 | EP2190287A1 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety |
| 06/02/2010 | EP2190286A1 Spiroindenes and spiroindanes as modulators of chemokine receptors |
| 06/02/2010 | EP2099799B1 Spiro-piperidine derivatives |
| 06/02/2010 | EP2059521B1 Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions |
| 06/02/2010 | EP2049532B1 Cgrp receptor antagonists |
| 06/02/2010 | EP2032563B1 Benzimidazol substituted thiophene derivatives with activity on plk |
| 06/02/2010 | EP2029601B1 Pyridopyrimidinone derivatives |
| 06/02/2010 | EP2001478B1 Cyclohexyl or piperidinyl carboxamide antibiotic derivatives |
| 06/02/2010 | EP1928993B1 Proanthocyanidin tannin composition, production method thereof and use of same |
| 06/02/2010 | EP1907386B1 Amino acid salts of rosiglitazone |
| 06/02/2010 | EP1890672B1 Use of chromone derivatives |
| 06/02/2010 | EP1853581B1 2-sulfinyl- and 2-sulfonyl-substituted imidazole derivatives and their use as cytokine inhibitors |
| 06/02/2010 | EP1833811B1 Oxygen containing heterocycles as glycine transporter inhibiting compounds |
| 06/02/2010 | EP1833477B1 Pyrazolo-heteroaryl compounds useful to treat tnf-alpha and il-1 mediated diseases |
| 06/02/2010 | EP1831211B1 Indazole-carboxamide compounds |
| 06/02/2010 | EP1817317B1 Methods for preparing pimecrolimus |
| 06/02/2010 | EP1817057B1 Sodium stibogluconate and il-2 for treating cancer |
| 06/02/2010 | EP1790643B1 Quinuclidine compounds having quaternary ammonium group, it's preparation method and use as blocking agents of acetycholine |
| 06/02/2010 | EP1773772B1 New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission |
| 06/02/2010 | EP1753309B1 Food compositions containing creatine |
| 06/02/2010 | EP1745040B9 Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors |
| 06/02/2010 | EP1712642B1 Method of examining sensitivity of cancer cell to anticancer agent |
| 06/02/2010 | EP1658263B1 Novel aminobenzophenone compounds |
| 06/02/2010 | EP1644012B1 Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in the preparation of medicaments |